Resilience has expanded its strategic partnership with Eli Lilly and Company to increase US production of critical medicines, with new manufacturing investments in Ohio. The $750 million investment builds on a partnership first established in 2023.
The investment will expand Resilience’s advanced manufacturing operations in the Cincinnati region to include Lilly’s KwikPen injectable device for diabetes and obesity medicines. The expansion will create at least 400 new high-skilled jobs, bringing total Resilience-created jobs in Ohio to more than 1,400. Site preparation is underway, with full operations expected to begin in early 2027.
The partnership has already produced more than 150 million doses of Lilly medicines for US patients in vial and pre-filled syringe formats. Resilience operates two advanced facilities in the Cincinnati region totaling nearly 1 million square feet and employing nearly 1,000 team members. The company recently established its global headquarters in Blue Ash, Ohio.
KEY QUOTES:
“We are proud of what we have built together with Lilly and this new expansion as we scale production of complex medicines in Ohio. Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States.”
William S. Marth, President and CEO, Resilience
“As demand for our medicines continues to increase, scaling complex manufacturing programs requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time. Today’s announcement highlights Resilience’s role as a strong partner to Lilly in strengthening domestic supply of high-demand treatments.”
Edgardo Hernandez, Executive Vice President and President, Manufacturing Operations, Lilly
“Resilience is an example of Ohio’s emerging leadership in biomanufacturing. The company’s recent headquarters move from California to Blue Ash and today’s announcement of an expanded partnership with Lilly further validates the state’s life science workforce, infrastructure, and collaborative approach to economic development.”
Governor Mike DeWine, Ohio
